One of the most closely watched cardiovascular trials of the year has returned a negative result. Novartis announced on September 4 that pelacarsen, an experimental injection designed to lower lipoprotein(a), did not reduce the risk of major cardiovascular events in an 8,323-patient late-stage trial, even though it succeeded in lowering the target it was built to attack.
The company said the Lp(a)HORIZON trial missed its primary endpoint, a combination of cardiovascular death, non-fatal heart attack, non-fatal stroke and urgent coronary revascularization requiring hospitalization, compared with placebo.
That outcome reaches beyond one drug. Elevated Lp(a) is an inherited risk factor that affects roughly one in five people worldwide and nearly a third of those with premature cardiovascular disease. It is largely fixed at birth, and diet and exercise barely move it. For patients who have been told they carry a genetic marker they cannot change, this trial was supposed to be the answer.
The Trial That Was Built to Answer One Question
Lp(a)HORIZON enrolled patients with established cardiovascular disease and Lp(a) at or above 70 mg/dL, with a separate analysis of those at or above 90 mg/dL. Everyone in the study was already receiving guideline-directed care, including cholesterol-lowering and blood pressure medication. The design is registered as NCT04023552 on ClinicalTrials.gov.
That design detail is central to interpreting the result. The trial asked whether lowering Lp(a) reduces the risk that remains after standard treatment has already been optimized. Novartis reported that pelacarsen did lower Lp(a) levels in that population, but that the reduction did not translate into fewer cardiovascular events overall.
Pelacarsen is an antisense oligonucleotide, a class of medicine that blocks production of a target protein rather than clearing it from the blood after it is made. Novartis holds global rights to the drug under a license and collaboration agreement with Ionis Pharmaceuticals.
Shreeram Aradhye, the company's president of development and chief medical officer, said the findings advance scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes, and may help inform future approaches to risk management. He was blunt about the result itself: "These are not the results we hoped for."
Lp(a) Testing Still Matters Even Without a Drug to Lower It
Nothing in this announcement changes current cholesterol guidance, and nobody should stop a statin, a PCSK9 inhibitor or a blood pressure medication because of it. Those treatments were the backdrop against which pelacarsen was tested, and they remain the foundation of care.
Both US and European guidelines recommend measuring Lp(a) once in a lifetime for all adults, and that recommendation stands. A high reading does not currently unlock a specific drug, but it does identify people who benefit from more aggressive management of everything that can be modified, including LDL cholesterol, blood pressure, smoking, and diabetes. It also flags a heritable trait that may prompt testing of first-degree relatives.
Lp(a) is different from the LDL cholesterol most people track. LDL responds to statins, diet, and exercise. Lp(a) is roughly 90 percent genetically determined and barely moves with lifestyle change, which is why a normal cholesterol panel can coexist with substantial inherited risk. It contributes to plaque buildup and inflammation in the arteries and has also been linked to narrowing of the aortic valve.
Cost and access shape who gets tested at all. Lp(a) is a single blood test, often ordered alongside a standard lipid panel, but coverage varies by insurer, and it is not part of routine screening in most primary care visits. Patients with early heart disease, a strong family history or unexplained cardiovascular events have the strongest case for asking about it. Because the trait is inherited, a high result in one family member is a reasonable prompt to test parents, siblings and adult children.
The Limits of a Topline Press Release
This is a company announcement, not a published paper. Novartis has released the headline conclusion without the full data, and said the results will be presented at an upcoming medical congress that has not yet been named.
Several important things are unknown. The magnitude of Lp(a) reduction achieved has not been disclosed, nor have results in the higher-threshold subgroup with Lp(a) at or above 90 mg/dL, nor whether any secondary endpoint favored the drug. Safety findings have not been detailed. Until the full dataset is presented and peer-reviewed, the only confirmed statement is that the primary endpoint was not met.
The result also does not overturn the genetic and epidemiological evidence that elevated Lp(a) is causally linked to cardiovascular disease. It shows that one drug, at one dose, in one population already receiving optimized therapy, did not produce a measurable event reduction over the study period. Whether other Lp(a)-lowering approaches in development fare differently is now the open question, and several remain in late-stage testing.
There are several ways a trial like this can miss without the underlying biology being wrong. The Lp(a) reduction achieved may not have been deep enough, the patients may have been treated too late in the course of their disease, or the follow-up period may have been too short for a difference in events to emerge. Distinguishing among those explanations requires the full dataset, which is exactly what has not been released.
Next Steps for Patients with High Lp(a) Readings
People already enrolled in pelacarsen studies should follow instructions from their trial site rather than acting on a press release. Patients waiting for an Lp(a) drug should talk with a cardiologist about what else in their risk profile can still be lowered, since that is where the available evidence sits.
MedicalDaily previously reported on what a large statin trial showed in older adults, a reminder that established therapies keep producing measurable benefit even as newer targets prove harder than expected.
Anyone with chest pain, sudden weakness or numbness on one side, difficulty speaking, or sudden severe shortness of breath needs emergency care regardless of any lab value. MedicalDaily will report the full Lp(a)HORIZON dataset when Novartis presents it.
Key Questions Answered
What happened with pelacarsen? Novartis announced that its Phase 3 Lp(a)HORIZON trial did not meet its primary endpoint. The drug lowered Lp(a) levels but did not reduce cardiovascular death, non-fatal heart attack, non-fatal stroke, or urgent coronary revascularization compared with placebo.
What is Lp(a)? Lipoprotein(a) is a particle in the blood whose level is roughly 90 percent genetically determined. It contributes to plaque buildup and inflammation in arteries and is an independent risk factor for cardiovascular disease.
How many people have elevated Lp(a)? About one in five people worldwide, and nearly a third of people with premature cardiovascular disease.
Should people still get tested? Yes. US and European guidelines recommend a once-in-a-lifetime Lp(a) measurement for adults. A high result identifies people who need tighter control of every other modifiable risk factor.
Does this change current heart medication guidance? No. Statins, PCSK9 inhibitors, and blood pressure treatments are unaffected. Nobody should stop a prescribed medication based on this announcement.
What is still unknown? The full dataset has not been released. The size of the Lp(a) reduction, results in the higher-Lp(a) subgroup, secondary endpoints, and detailed safety findings have not been made public.
When will more information be available? Novartis said the trial data will be presented at an upcoming medical congress. No date has been announced.
